Ehrlich Biotechnology Co. Ltd. has described antibody-drug conjugates comprising an antibody targeting EGFR (HER1; erbB1) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKB α) (Glu17Lys mutant) inhibitors reported to be useful for the treatment of leukemia.
Amira Therapeutics SL has announced new preclinical findings for its lead compound AMI-463, which is being developed primarily for rhabdomyosarcoma, the most common soft tissue sarcoma in children. AMI-463 is a first-in-class inhibitor that blocks the cell adhesion molecule (CAM)-related down-regulated by oncogenes (CDON).
Cartography Biosciences Inc. has received IND approval from the FDA for CBI-1214, a T-cell engager being developed for the treatment of colorectal cancer.
Researchers from Chimerix, now part of Jazz Pharmaceuticals, presented preclinical data on ONC-206, a compound that functions as both an agonist of the mitochondrial protease Caseinolytic peptidase P (CLPP) and an antagonist of the G protein-coupled receptor DRD2, in models of triple-negative breast cancer (TNBC).
Werewolf Therapeutics Inc. has announced that its priorities for the coming year include a focus on the company’s Inducer T-cell engager platform, where preclinical studies have demonstrated robust silencing and reduction of off-tumor toxicity.
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers new clues for future therapies. Glioblastoma is one of the deadliest brain cancers, accounting for about half of all brain tumors, with a median survival rate of just 15 months. Despite surgery and chemotherapy, more than 1,250 clinical trials over the past 20 years have struggled to improve survival rates.
Alicorn Pharmaceutical Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Liaoning Haisco Pharmaceutical Co. Ltd. has identified crystalline salts of known cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
RSS
